Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company is part of a new ...

Sam Altman’s longevity startup Retro Bio seeks to raise $5 billion valuation; Trump pollster advises House GOP on healthcare policy strategy; BMS extends timeline for Cobenfy trial data readout.

"You could really, in a very fundamental sense, talk about redrawing the border around a brain," Hodak says, "possibly to ...

It’s nearly Christmas time, and this is the time of year when Time magazine announces its illustrious “Person of the Year,” ...

Either way, Santa Clara University’s thought leaders have you covered. We asked a handful of our faculty scholars from across ...

Silicon Valley and other high tech billionaires are investing millions in start-ups dedicated to creating genetically engineered (GE) babies, according to a recent Wall Street Journal (WSJ) report. AI ...

We came across a bullish thesis on Bio-Techne Corporation on Valueinvestorsclub.com by rab. In this article, we will summarize the bulls’ thesis on TECH.

These PE ratios are a little high — a “normal” PE ratio is typically somewhere in the 20s — but they’re not outrageous. All three stocks have actually seen decreases in PE ratio in recent years. Plus, ...

Bristol Myers Squibb said it will enroll more patients in a key Phase 3 trial studying its drug Cobenfy in psychosis associated with Alzheimer’s disease, after the company found “irregularities due to ...

AI is already sufficiently robust that it introduces new global risks and exacerbates existing threats. Its development is ...